Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Study of Single Escalating Doses of BI 1034020 Administered Intravenously or Subcutaneously to Male Healthy Volunteers
- First Posted Date
- 2013-10-08
- Last Posted Date
- 2015-07-30
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 35
- Registration Number
- NCT01958060
- Locations
- 🇩🇪
1312.1.1 Boehringer Ingelheim Investigational Site, Biberach, Germany
🇩🇪1312.1.2 Boehringer Ingelheim Investigational Site, Ingelheim, Germany
BI 113608 Administered as Tablets Twice Daily Over 4 Weeks in Patients With Chronic Obstructive Pulmonary Disease Associated With Chronic Bronchitis
- Conditions
- Pulmonary Disease, Chronic Obstructive
- Interventions
- Drug: Placebo to BI 113608 medium dose b.i.d.Drug: Placebo to BI 113608 high dose b.i.d.Drug: Placebo to BI 113608 low dose b.i.d.Drug: BI 113608 medium dose b.i.d.Drug: BI 113608 high dose b.i.d.Drug: BI 113608 low dose b.i.d.
- First Posted Date
- 2013-10-08
- Last Posted Date
- 2017-01-20
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 84
- Registration Number
- NCT01958008
- Locations
- 🇩🇪
Boehringer Ingelheim Investigational Site, Mannheim, Germany
Phase I Dose Escalation Trial of Volasertib in Combination With Azacitidine in Patients With MDS or CMML
- Conditions
- Leukemia, Myelomonocytic, ChronicMyelodysplastic Syndromes
- Interventions
- First Posted Date
- 2013-10-08
- Last Posted Date
- 2019-02-08
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 16
- Registration Number
- NCT01957644
- Locations
- 🇫🇷
1230.33.33002 Boehringer Ingelheim Investigational Site, Marseille, France
🇫🇷1230.33.33001 Boehringer Ingelheim Investigational Site, Paris, France
🇩🇪1230.33.49002 Boehringer Ingelheim Investigational Site, Dresden, Germany
Safety, Tolerability, PK and PD of BI 655075 and Establishment of BI 655075 Dose(s) Effective to Reverse Prolongation of Blood Coagulation Time by Dabigatran
- First Posted Date
- 2013-10-07
- Last Posted Date
- 2016-02-11
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 46
- Registration Number
- NCT01955720
- Locations
- 🇧🇪
1321.2.1 Boehringer Ingelheim Investigational Site, Antwerpen, Belgium
Safety and Efficacy of BI 695500 in Patients With Moderately to Severely Active Rheumatoid Arthritis
- First Posted Date
- 2013-10-07
- Last Posted Date
- 2018-01-18
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 91
- Registration Number
- NCT01955733
- Locations
- 🇺🇸
1301.4.5809 Boehringer Ingelheim Investigational Site, Pembroke Pines, Florida, United States
🇺🇸1301.4.5585 Boehringer Ingelheim Investigational Site, Birmingham, Alabama, United States
🇺🇸1301.4.5765 Boehringer Ingelheim Investigational Site, El Cajon, California, United States
Afatinib (BIBW 2992) in Advanced Non-Small Cell Lung Cancer Patients With EGFR Mutation
- First Posted Date
- 2013-10-01
- Last Posted Date
- 2019-08-12
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 542
- Registration Number
- NCT01953913
- Locations
- 🇨🇳
Zhejiang Cancer Hospital, Hangzhou, China
🇨🇳Shanghai Chest Hospital, Shanghai, China
🇨🇳Shanghai Pulmonary Hospital, Shanghai, China
To Determine the Maximum Tolerated Dose (MTD) of BIBF 1120 in Patients With Solid Tumours
- First Posted Date
- 2013-09-27
- Last Posted Date
- 2013-09-27
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 61
- Registration Number
- NCT01951846
- Locations
- 🇩🇪
Klinik für Tumorbiologie, Abteilung Internistische Onkologie, Freiburg, Germany
Pharmacokinetics and Pharmacodynamics of BI 695500 vs. Rituximab as First Line-treatment in Patients With Low Tumor Burden Follicular Lymphoma
- First Posted Date
- 2013-09-25
- Last Posted Date
- 2018-09-05
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 95
- Registration Number
- NCT01950273
- Locations
- 🇧🇪
UZ Leuven, Leuven, Belgium
🇩🇪Haemato-Onkologie Hamburg, Hamburg, Germany
🇩🇪Klinikum Kassel GmbH, Kassel, Germany
Post Prandial Glucose (PPG) Study of Empagliflozin in Japanese Patients With Type 2 Diabetes Mellitus
- First Posted Date
- 2013-09-23
- Last Posted Date
- 2014-12-24
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 60
- Registration Number
- NCT01947855
- Locations
- 🇯🇵
1245.35.002 Boehringer Ingelheim Investigational Site, Shinjyuku-ku, Tokyo, Japan
🇯🇵1245.35.001 Boehringer Ingelheim Investigational Site, Suita-shi, Osaka, Japan
Two-way Crossover Study in Healthy Male and Female Subjects to Evaluate the Bioequivalence of Jentadueto®.
- First Posted Date
- 2013-09-20
- Last Posted Date
- 2015-02-25
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 36
- Registration Number
- NCT01947153
- Locations
- 🇷🇺
1288.21.1 Boehringer Ingelheim Investigational Site, St. Petersburg, Russian Federation